Sample‐to‐answer salivary miRNA testing: New frontiers in point‐of‐care diagnostic technologies
WIREs Nanomedicine and Nanobiotechnology · 2024-05 · 16 (3)
DOI: 10.1002/wnan.1969 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift WIREs Nanomedicine and Nanobiotechnology, online erschienen am 23.05.2024. Verfasst von Zhikun Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Electrical Engineering, Pennsylvania State University, University Park, Pennsylvania, USA. Hauptthemen laut MEDLINE: MicroRNAs, Saliva, Point-of-Care Testing. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 191 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, National Science Foundation, NIAID NIH HHS.
Abstract (Originalsprache)
MicroRNA (miRNA), crucial non‐coding RNAs, have emerged as key biomarkers in molecular diagnostics, prognosis, and personalized medicine due to their significant role in gene expression regulation. Salivary miRNA, in particular, stands out for its non‐invasive collection method and ease of accessibility, offering promising avenues for the development of point‐of‐care diagnostics for a spectrum of diseases, including cancer, neurodegenerative disorders, and infectious diseases. Such development promises rapid and precise diagnosis, enabling timely treatment. Despite significant advancements in salivary miRNA‐based testing, challenges persist in the quantification, multiplexing, sensitivity, and specificity, particularly for miRNA at low concentrations in complex biological mixtures. This work delves into these challenges, focusing on the development and application of salivary miRNA tests for point‐of‐care use. We explore the biogenesis of salivary miRNA and analyze their quantitative expression and their disease relevance in cancer, infection, and neurodegenerative disorders. We also examined recent progress in miRNA extraction, amplification, and multiplexed detection methods. This study offers a comprehensive view of the development of salivary miRNA‐based point‐of‐care testing (POCT). Its successful advancement could revolutionize the early detection, monitoring, and management of various conditions, enhancing healthcare outcomes. This article is categorized under: Diagnostic Tools > Biosensing Diagnostic Tools > Diagnostic Nanodevices
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Electrical Engineering, Pennsylvania State University, University Park, Pennsylvania, USA.
- Department of Biomedical Engineering, Pennsylvania State University, University Park, Pennsylvania, USA.
ORCID-Profile: Zhikun Zhang, Md Ahasan Ahamed, Weihua Guan
Förderung
- NIH HHS
- National Science Foundation
- NIAID NIH HHS
- National Institutes of Health
Zitieren
APA
Zhang, Z., Liu, T., Dong, M., Ahamed, M. A., & Guan, W. (2024). Sample‐to‐answer salivary miRNA testing: New frontiers in point‐of‐care diagnostic technologies. WIREs Nanomedicine and Nanobiotechnology, 16(3). https://doi.org/10.1002/wnan.1969
Vancouver
Zhang Z, Liu T, Dong M, Ahamed MA, Guan W. Sample‐to‐answer salivary miRNA testing: New frontiers in point‐of‐care diagnostic technologies. WIREs Nanomedicine and Nanobiotechnology. 2024;16(3). doi:10.1002/wnan.1969
BibTeX
@article{Zhang2024,
author = {Zhang, Zhikun and Liu, Tianyi and Dong, Ming and Ahamed, Md Ahasan and Guan, Weihua},
title = {Sample‐to‐answer salivary miRNA testing: New frontiers in point‐of‐care diagnostic technologies},
journal = {WIREs Nanomedicine and Nanobiotechnology},
year = {2024},
volume = {16},
number = {3},
doi = {10.1002/wnan.1969}
}
EUVIMED